Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced receiving a patent award from the China National Intellectual Property Administration (CNIPA) for its in-house developed human antibody mice RenMab platform. The patent, titled “Genetically modified non-human animals with humanized immunoglobulin loci”, is valid through February 18, 2040.
RenMab Technology Platform and Its Global Reach
The RenMab technology platform is pivotal in improving the efficiency of human antibody drug development and accelerating the development process. Recognizing its significance, Biocytogen has filed for patent protection in several key jurisdictions, including the US, Europe, Japan, Singapore, Russia, Israel, and Australia. This global protection underscores the platform’s innovative nature and its potential impact on the field of antibody drug development.
Enhancing Drug Development with RenMab
The RenMab platform’s patent award from CNIPA further solidifies Biocytogen’s position as a leader in the development of human antibody therapeutics. The platform’s ability to streamline the drug development process is a significant advancement, offering a more efficient pathway to bringing life-saving treatments to market.-Fineline Info & Tech
